"Entering 2023 with a new corporate strategy and a focus on delivering profitable growth, our team is uniquely positioned to enable precision medicine by combining the power of scalable genomic sequence analysis with data from our Centrellis(R) platform," said Katherine Stueland, CEO of GeneDx. "We have a significant opportunity to grow testing in pediatric rare disease, expand into the adult and newborn screening markets, and build our data information business. With our strong balance sheet following the successful closing of our recent public offering, we are fully funded through our expected profitability in 2025."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on WGS:
- GeneDx Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
- GeneDx to Participate in the Cowen 43rd Annual Healthcare Conference
- GeneDx honors Rare Disease Day and announces presentations and research at the 2023 American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting
- GeneDx to Report Fourth Quarter and Full Year 2022 Financial Results on Tuesday, March 14th, 2023
- GeneDx rare disease data demonstrates utility in drug candidate identification
